NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Antiemetics: American Society of Clinical Oncology Focused Guideline Update

(2016) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

(2014) P. J. Hesketh et al.   ANNALS OF ONCOLOGY

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

(2014) R. J. Gralla et al.   ANNALS OF ONCOLOGY

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

(2014) M. Aapro et al.   ANNALS OF ONCOLOGY

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice

(2014) Mary Lou Affronti et al.   SUPPORTIVE CARE IN CANCER

Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells

(2014) Ajit G. Thomas et al.   EXPERIMENTAL BRAIN RESEARCH

Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study

(2014) James W. Gilmore et al.   Journal of Oncology Practice

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

(2012) M. Aapro et al.   ANNALS OF ONCOLOGY

Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects

(2012) Marigo Stathis et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Update and new trends in antiemetic therapy: the continuing need for novel therapies

(2010) P. Feyer et al.   ANNALS OF ONCOLOGY

Abstracts of the 2009 international MASCC/ISOO symposium

(2009)   SUPPORTIVE CARE IN CANCER

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER